All In Biotech

Drug Trial Radar · NCT02720692

Evaluation of N1539 Following Major Surgery

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety of N1539 Following Major Surgery

Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 722 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

722

Actual

Start

Mar 2016

Primary completion

Mar 2017

Study completion May 2017

Sponsor

Lead sponsor
Baudax BioIndustry
Sponsor type
Industry
First posted
Mar 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.

Conditions

  • Pain, Post-operative

Interventions

  • N1539Drug

  • Intravenous PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Adverse EventsTime frame: 28 Days

Locations

32 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Florence, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Sheffield, Alabama

  • Site not named

    Gilbert, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Bakersfield, California

  • Site not named

    Miami, Florida

  • Site not named

    Tamarac, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Great Falls, Montana

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Tyrone, Pennsylvania

  • Site not named

    Hendersonville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Chermside, Queensland, Australia

  • Site not named

    Kippa-Ring, Queensland, Australia

  • Site not named

    Southport, Queensland, Australia

  • Site not named

    Richmond, Victoria, Australia

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Kingston, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Auckland, New Zealand

  • Site not named

    Christchurch, New Zealand

  • Site not named

    Hamilton, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.